Pfizer's CEO, Albert Bourla, expressed concerns that tariff uncertainties are impacting the company’s ability to make significant investments in the US. During a recent earnings call, Bourla indicated that stable tariff conditions could lead to considerable investments in both research and manufacturing. He highlighted that during uncertain times, Pfizer is adopting a cautious investment approach to manage costs. Furthermore, Bourla noted that Pfizer has multiple manufacturing sites operational in the US and is prepared to shift production quickly if needed, yet the tariffs remain a financial burden for the company as projected costs could reach $150 million by 2025.
"If I know that there will not be tariffs and a heavy certainty, then there are tremendous investments that can happen in this country, both in R&D and manufacturing."
"And in periods of uncertainty, everybody is controlling their cost as we are doing. We are being very frugal with investments so we can be prepared for any day."
Collection
[
|
...
]